This content is machine translated Plaque psoriasis New “Real World” Study on Tildrakizumab In a retrospective study of 30 patients with moderate to severe plaque psoriasis, the use of the IL-23 inhibitor tildrakizumab was shown to be effective and safe in clinical practice.…
View Post 6 min This content is machine translated Study Report Palmoplantar psoriasis – a diagnostic challenge Because many clinical and histopathologic features of palmoplantar psoriasis (PP) overlap with those of other dermatoses, differential diagnosis is far from trivial. With this in mind, a research team analyzed…
View Post 3 min This content is machine translated Plaque psoriasis Current 5-year data on secukinumab A long-term extension analysis of the ERASURE and FIXTURE studies recently published in the British Journal of Dermatology demonstrates the long-lasting efficacy and safety of secukinumab in patients with moderate-to-severe…
View Post 8 min This content is machine translated Translational medicine Psoriasis – from immunopathogenesis to successful therapy The innovative systemic treatments for psoriasis are a prime example of translational medicine. In a review published last year in the Journal of Investigative Dermatology, Prof. Peter van de Kerkhof,…
View Post 7 min This content is machine translated Medicalonline Long-term data on upadacitinib show a consistent safety profile and no new safety signals [1]. * With the exception of the already known higher herpes zoster and NMSC events and higher CPK levels.
View Post 5 min This content is machine translated Systemic lupus erythematosus (SLE) Anifrolumab: 3-year data confirm long-term clinical benefit New data from a long-term extension study show that anifrolumab was effective, safe, and tolerable in systemic lupus erythematosus (SLE) even in long-term use over three years [1]. Two post-hoc…
View Post 3 min This content is machine translated Plaque psoriasis TYK2 inhibition shows great therapeutic potential Psoriasis is nowadays understood as a systemic disease, which is based on chronic inflammation. Research into the etiopathogenesis, as well as the establishment of new active substances, is progressing rapidly.…
View Post 6 min This content is machine translated Giant cell arteritis: classification and treatment What’s new? Das vom American College of Rheumatology (ACR) und der European League against Rheumatology (EULAR) gemeinsam entwickelte und 2022 veröffentlichte Update der Klassifikationskriterien für Riesenzellarteriitis trägt insbesondere den Fortschritten im Bereich…
View Post 4 min This content is machine translated Biologics for psoriasis “Drug Survival” under the microscope The era of biologics has revolutionized the treatment options for patients with moderate to severe psoriasis in recent decades. Drug survival is an indicator of the longer-term efficacy and safety…
View Post 3 min This content is machine translated Multiple sclerosis RAW, PIRA and the disability progression – an overview. Patients with multiple sclerosis acquire disability either through relapse-associated deterioration (RAW) or relapse-independent progression (PIRA). One study now addressed the questions of how early progression begins in the course of…
View Post 5 min This content is machine translated Psoriasis: "Awareness" of comorbidities Cardiometabolic diseases and other comorbidities In addition to certain risk and trigger factors, psoriasis is associated with various comorbidities, such as metabolic syndrome, cardiovascular disease, and depression. This is particularly true for patients with moderate…
